Author(s): Sakellariou GT, Chatzigiannis I
Abstract Share this page
Abstract Anti-TNFalpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFalpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFalpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.
This article was published in Clin Rheumatol
and referenced in Journal of Antivirals & Antiretrovirals